PR88538

SINGAPORE, March 16, 2021 /PRNewswire=KYODO JBN/--

GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) receives the

"Best Contract Research Organization Award" on the 4th Annual Asia Pacific

Bioprocessing Excellence Awards Ceremony 2021 held on 16th March 2021.

The award follows GenScript's CDMO segment, GenScript Probio recognition at the

Korea Bioprocessing Excellence Awards in 2020 for the "Bioprocessing Excellence

in CDMO Services".

The Asia-Pacific Bioprocessing Excellence Awards seeks to give recognition to

exceptional bioprocessing experts, organizations and technologies that

facilitate bio manufacturing excellence at enhanced speed, reduced cost and

superior quality. GenScript is recognized to provide excellent CRO services

with strong technical capabilities and reasonable cost without compromising on

the quality of service.

GenScript is a global leading life sciences research and application service

and product provider with best in class capabilities comprising gene synthesis,

molecular biology, peptide synthesis, custom antibodies, protein expression,

antibody and protein engineering service, and in-vitro and in-vivo

pharmacology. Leveraging in the Group's proprietary technology and know-hows,

GenScript has established major platforms including contracted research

organization ("CRO") platform to provide one-stop solutions to global research

communities.

"We are honored to have won this prestigious award for best contract research

organization, being recognized by the industry in this category is a real

testament to the quality of service that GenScript offers," said Mr. Johnson

Wang, President of GenScript Asia Pacific Division. "A commitment to creating a

series of partnerships with our customers to guarantee the quality of our

services and consistently exceeding their expectations is a fundamental value

for our highly skilled global team. One of the example is the cPass™ kit which

we collaborated with Prof Wang Linfa from Duke-NUS Medical School Singapore and

A*Star Diagnostic Development hub to launch the first-in-the-world kit which

detects functional neutralizing antibodies. We will continue to provide and

deliver high quality services to the research community in Asia Pacific region

and also the rest of the world."

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology

group. Based on its leading gene synthesis technology, GenScript has developed

four major platforms including the global cell therapy platform, the biologics

contract development and manufacturing organization (CDMO) platform, the

contract research organization (CRO) platform and the industrial synthesis

product platform.

GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong

Stock Exchange in 2015. GenScript's business operations span over 100 countries

and regions worldwide with legal entities located in the US, Mainland China,

Hong Kong, Japan, Singapore, the Netherlands and Ireland. GenScript provides

premium, convenient, and reliable products and services for over 100,000

customers.

For more information visit http://www.genscript.com.

Source: GenScript Biotech Singapore Pte Ltd

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=386740

   Caption: Mr. Johnson Wang, President of GenScript Asia Pacific Division giving speech

during the 4th Asia Pacific Bioprocessing Excellence Award.